William Haning to Central Nervous System Stimulants
This is a "connection" page, showing publications William Haning has written about Central Nervous System Stimulants.
Connection Strength
2.031
-
Park TM, Haning WF. Stimulant Use Disorders. Child Adolesc Psychiatr Clin N Am. 2016 Jul; 25(3):461-71.
Score: 0.469
-
Nakama H, Chang L, Cloak C, Jiang C, Alicata D, Haning W. Association between psychiatric symptoms and craving in methamphetamine users. Am J Addict. 2008 Sep-Oct; 17(5):441-6.
Score: 0.278
-
Haning W, Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction. 2007 Apr; 102 Suppl 1:70-5.
Score: 0.252
-
Smith LM, Diaz S, LaGasse LL, Wouldes T, Derauf C, Newman E, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Neal C, Lester BM. Developmental and behavioral consequences of prenatal methamphetamine exposure: A review of the Infant Development, Environment, and Lifestyle (IDEAL) study. Neurotoxicol Teratol. 2015 Sep-Oct; 51:35-44.
Score: 0.112
-
Li MD, Wang J, Niu T, Ma JZ, Seneviratne C, Ait-Daoud N, Saadvandi J, Morris R, Weiss D, Campbell J, Haning W, Mawhinney DJ, Weis D, McCann M, Stock C, Kahn R, Iturriaga E, Yu E, Elkashef A, Johnson BA. Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction. BMC Med Genomics. 2014 Dec 12; 7:65.
Score: 0.107
-
Liles BD, Newman E, Lagasse LL, Derauf C, Shah R, Smith LM, Arria AM, Huestis MA, Haning W, Strauss A, Dellagrotta S, Dansereau LM, Neal C, Lester BM. Perceived child behavior problems, parenting stress, and maternal depressive symptoms among prenatal methamphetamine users. Child Psychiatry Hum Dev. 2012 Dec; 43(6):943-57.
Score: 0.093
-
Shah R, Diaz SD, Arria A, LaGasse LL, Derauf C, Newman E, Smith LM, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Roberts MB, Neal C, Lester BM. Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012 May; 29(5):391-400.
Score: 0.089
-
Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, Kahn R, Chiang N, Beresford T, Campbell J, Haning W, Mawhinney J, McCann M, Rawson R, Stock C, Weis D, Yu E, Elkashef AM. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012 Jan 01; 120(1-3):135-41.
Score: 0.085
-
Zabaneh R, Smith LM, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Dansereau LM, Lin H, Neal C, Lester BM. The effects of prenatal methamphetamine exposure on childhood growth patterns from birth to 3 years of age. Am J Perinatol. 2012 Mar; 29(3):203-10.
Score: 0.085
-
Nguyen D, Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr. 2010 Aug; 157(2):337-9.
Score: 0.078
-
Gray TR, Kelly T, LaGasse LL, Smith LM, Derauf C, Grant P, Shah R, Arria A, Haning W, Della Grotta S, Strauss A, Lester BM, Huestis MA. New meconium biomarkers of prenatal methamphetamine exposure increase identification of affected neonates. Clin Chem. 2010 May; 56(5):856-60.
Score: 0.077
-
Gray TR, Kelly T, LaGasse LL, Smith LM, Derauf C, Haning W, Grant P, Shah R, Arria A, Strauss A, Lester BM, Huestis MA. Novel biomarkers of prenatal methamphetamine exposure in human meconium. Ther Drug Monit. 2009 Feb; 31(1):70-5.
Score: 0.071
-
Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Fallone M, Liu J, Lester BM. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol. 2008 Jan-Feb; 30(1):20-8.
Score: 0.065
-
Elkashef A, Rawson RA, Smith E, Pearce V, Flammino F, Campbell J, Donovick R, Gorodetzky C, Haning W, Mawhinney J, McCann M, Weis D, Williams L, Ling W, Vocci F. The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. Addiction. 2007 Apr; 102 Suppl 1:107-13.
Score: 0.063
-
Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, Huestis M, Haning W, Strauss A, Della Grotta S, Liu J, Lester BM. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. 2006 Sep; 118(3):1149-56.
Score: 0.060
-
Kirlic N, Newman E, Lagasse LL, Derauf C, Shah R, Smith LM, Arria AM, Huestis MA, Haning W, Strauss A, Dellagrotta S, Dansereau LM, Abar B, Neal CR, Lester BM. Cortisol reactivity in two-year-old children prenatally exposed to methamphetamine. J Stud Alcohol Drugs. 2013 May; 74(3):447-51.
Score: 0.024
-
Smith LM, Paz MS, LaGasse LL, Derauf C, Newman E, Shah R, Arria A, Huestis MA, Haning W, Strauss A, Della Grotta S, Dansereau LM, Neal C, Lester BM. Maternal depression and prenatal exposure to methamphetamine: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012 Jun; 29(6):515-22.
Score: 0.022